Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary indicates strong financial metrics with raised EPS guidance, significant cost savings initiatives, and ongoing product development in high-potential areas like lung cancer. Despite lower COVID-19 product performance, non-COVID products are doing well. The Q&A session revealed optimism about product pipelines and strategic AI investments. While some details were deferred, the overall sentiment is positive due to promising R&D advancements and strategic initiatives. The lack of specific market cap data limits precise impact prediction, but the positive aspects outweigh negatives, suggesting a positive stock reaction.
Key Financial Performance
Full Year 2025 Revenue $62.6 billion, a 2% operational decline year-over-year. Excluding COVID-19 products, operational revenue growth was 6%. The decline was primarily due to reduced demand for COVID-19 products.
Adjusted Gross Margins (Full Year 2025) 76%, in line with expectations. This reflects cost improvements across the manufacturing network.
Diluted EPS (Full Year 2025) $1.36, compared to $1.41 last year. Adjusted diluted EPS was $3.22, up from $3.11 last year, driven by cost management and operational efficiencies.
Recently Launched and Acquired Products Revenue (Full Year 2025) $10.2 billion, growing approximately 14% operationally year-over-year. Growth was driven by strategic investments and product performance.
Fourth Quarter 2025 Revenue $17.6 billion, a 3% operational decline year-over-year. Non-COVID product revenue grew 9% operationally, while COVID product revenue declined approximately 40% due to reduced demand.
Adjusted Gross Margin (Fourth Quarter 2025) 71%, reflecting product mix changes, including lower COVID-19 product sales, and strong cost management.
Adjusted Operating Expenses (Fourth Quarter 2025) $7.4 billion, in line with last year. Adjusted SI&A expenses decreased 5% operationally due to focused investments and productivity improvements, while adjusted R&D expenses increased 4% operationally due to investments in oncology and obesity product candidates.
Adjusted Diluted EPS (Fourth Quarter 2025) $0.66, ahead of expectations due to strong gross margin and cost management performance.
Shareholder Returns (Full Year 2025) $9.8 billion returned via quarterly dividends, reflecting the company's commitment to shareholder value.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Metsera, YaoPharma, and 3SBio deals: These deals have strengthened Pfizer's pipeline and positioned the company for growth.
Padcev approval: FDA approved Padcev in combination with pembro for muscle-invasive bladder cancer, expanding the U.S. addressable population to approximately 22,500 patients.
Nurtec: Achieved 83% of new CGRP writer volume in Q4 2025, maintaining leadership in the oral CGRP class.
VESPER-3 study: Demonstrated robust weight loss with the ultra-long-acting GLP-1 receptor agonist '3944, supporting monthly dosing and competitive efficacy.
Obesity market: Pfizer is targeting a $150 billion market with its differentiated Metsera pipeline portfolio and other obesity-related programs.
Migraine portfolio: Global scaling of the migraine portfolio, including Nurtec, has strengthened Pfizer's market position.
Cost savings: Achieved $600 million in savings from Phase 1 of the Manufacturing Optimization Program in 2025, with additional savings expected in 2026 and 2027.
AI integration: Scaling AI across R&D, manufacturing, and commercial operations to improve productivity and accelerate innovation.
Seagen, Metsera, and Biohaven acquisitions: These acquisitions are transformative, focusing on maximizing product portfolios and accelerating pipeline development.
Post-2028 growth strategy: Investing in R&D, new product launches, and bolt-on business development to drive growth beyond 2028.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Patent Expirations: Several key products are expected to lose patent or regulatory exclusivity in the next few years, posing a risk to revenue streams.
COVID-19 Product Revenue Decline: Revenues from COVID-19 products, including Comirnaty and Paxlovid, have significantly declined due to reduced demand and narrow vaccine recommendations.
Regulatory and Development Challenges: The company faces challenges in achieving regulatory approvals and advancing its pipeline, particularly for new and innovative therapies.
Manufacturing Optimization: Efforts to optimize manufacturing and achieve cost savings may face execution risks, potentially impacting operational efficiency.
Economic and Market Conditions: Economic uncertainties and market conditions, including pricing pressures and competition, could adversely affect financial performance.
Integration of Acquisitions: The integration of recent acquisitions like Seagen, Metsera, and Biohaven presents operational and strategic challenges.
R&D Investment Risks: Significant investments in R&D, including AI and obesity programs, carry the risk of not yielding expected returns.
Supply Chain Risks: Potential disruptions in the supply chain could impact the timely delivery of products and operational efficiency.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: Pfizer expects total company full year 2026 revenues to be in the range of $59.5 billion to $62.5 billion. COVID product revenues are expected to trend lower again in 2026, with revenues of approximately $5 billion. Non-COVID product portfolio revenues are expected to grow approximately 4% operationally year-over-year, excluding COVID and LOE products.
Margin Projections: Pfizer anticipates mid-70s adjusted gross margins for 2026, with continued focus on strong cost management and manufacturing optimization.
Capital Expenditures and Investments: Pfizer plans to invest strategically in key assets and manage upcoming LOEs from 2026 to 2028. The company is committed to achieving $7.2 billion in total net cost savings from productivity programs by the end of 2026, with additional savings expected in 2027.
Pipeline and R&D Milestones: Pfizer anticipates progress with approximately 20 recently initiated and planned key pivotal studies in 2026, including 10 in the Metsera portfolio and four with the anti-PD-1 VEGF bispecific. Key Phase III readouts are expected for Elrexfio in multiple myeloma and the Lyme disease vaccine candidate. The company is targeting the first of a series of potential approvals in 2028 for its obesity program.
Market Trends and Strategic Plans: Pfizer is focusing on the next generation of therapies for chronic weight management, targeting a $150 billion market. The company is also scaling artificial intelligence across R&D, manufacturing, commercial, and patient engagement to improve productivity and accelerate innovation.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Total dividends returned to shareholders in 2025: $9.8 billion
Commitment to dividend growth: Pfizer remains committed to maintaining and growing its dividend over the long term.
Share repurchase program: Potential for value-enhancing share repurchases in the future, but no specific program was mentioned for 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you elaborate on the tolerability observed in the VESPER-3 data, specifically regarding vomit rates and differences between mild or moderate dosing arms?
A:The full tolerability data will be shared at the ADA in June. Observed distribution of adverse events (AEs) was consistent across weekly and monthly dosing. Despite a 4-fold higher dose, there were no significant increases in sudden discontinuations, nausea, or vomiting. The Phase III study will allow down-titration, unlike VESPER-3.
Q:What role does the profile of the two doses moving forward from VESPER-3 play in the market?
A:The clinical data suggests that '3944 has competitive efficacy with the standard of care and potentially best-in-class against mono-agonists. Monthly dosing offers a lower medication burden, which is appealing to patients, providers, and payers. It also provides an opportunity to switch patients from weekly to monthly therapy.
Q:How is the market for this category performing outside the U.S.?
A:The ex-U.S. market for this category is projected to be $150 billion, with 40% of that outside the U.S. There is a high willingness to pay out-of-pocket in mature markets like Europe, Australia, and Canada, with price points between $250 to $350. Emerging markets also show high prevalence and willingness to pay.
Q:Can you elaborate on the Phase III design for VESPER-6 and the flexibility for patients dealing with side effects?
A:The Phase III design for VESPER-6 will test different titrations and include a 9.6 mg dose (2.4 mg weekly equivalent). The study aims to improve the overall profile by allowing flexibility in dosing to manage side effects.
Q:What other data can we expect at ADA from internal programs or the Metsera portfolio?
A:Updated data on amylin and the combination of amylin plus '3944 will be shared. Early data showed additive weight loss of 5% at day 8 for the combination. Data on the GIPR antagonist oral and ultra-long GLP-1 (potentially 3-monthly) will also be presented.
Q:Did the placebo arm in the VESPER-3 data gain or lose weight?
A:The placebo arm was stable, with no significant weight gain or loss. Full data will be presented at ADA.
Q:Is monthly dosing the longest interval feasible for '3944, or could it be extended to every 2 months?
A:'3944 is designed as a monthly maintenance therapy. A separate molecule in Phase I is being tested for potential 3-monthly dosing.
Q:Will the Phase III programs include standard metabolic studies or explore other indications?
A:Initial Phase III programs will focus on metabolic studies, including VESPER-4, VESPER-5, and VESPER-6. Beyond that, seven additional studies are planned, exploring cardiovascular, metabolic, and other opportunities to differentiate.
Q:What are the baseline characteristics of the VESPER-3 study population?
A:The study was conducted in the U.S. only, with demographics typical of a small U.S.-based Phase II study. Detailed demographics will be presented at ADA.
Q:What is the duration of GI side effects with longer dosing intervals?
A:The tolerability profile is similar to the GLP-1 class, with no significant clustering of adverse events for monthly dosing. Severe nausea, vomiting, and diarrhea were minimal.
Q:Can you deliver a superior profile with your upcoming Phase III for B6A in second-line NSCLC?
A:The Phase III study for sigvotatug vedotin (B6A) in second-line NSCLC is ongoing. Single-agent activity showed a response rate over 30% and median overall survival of 16.3 months. Combination studies with pembrolizumab showed a 57% response rate and over 90% disease control rate.
Q:What is the status of portfolio realignment and the impact of AI investments?
A:Most portfolio pruning is complete, with a focus on four therapeutic areas. AI investments have improved productivity, enabling cost savings and reinvestment in R&D. AI is being embedded across functions, including discovery, clinical trials, and marketing.
Q:Was the 9.6 mg monthly dose for GLP monotherapy a reaction to the VESPER-3 data?
A:The 9.6 mg monthly dose (equivalent to 2.4 mg weekly) was planned based on prior modeling and is being tested in VESPER-4.
Q:What is the tolerability of the GLP plus amylin combo, and can it fit into a single pill?
A:The GLP plus amylin combo is a monthly subcutaneous injection, not a pill. Early data showed 5% weight loss at day 8, with updated data expected later this year.
Q:How does the GLP-1-amylin injectable combination compare to monotherapy?
A:The combination is expected to offer increased efficacy compared to monotherapy, targeting ultra-high efficacy tiers and addressing unmet needs like higher weight loss and better tolerability.
Q:What data was known about the oral GLP-1 in-licensed from YaoPharma?
A:The oral GLP-1 is in Phase I and was acquired through an exclusive agreement. It will be tested in combination with the GIPR antagonist.
Q:What are the expectations for the Lyme disease vaccine VALOR study?
A:The Phase III VALOR trial targets Lyme disease with a multivalent protein subunit vaccine. Results are expected in the first half of this year. The vaccine addresses a significant unmet need, with 400,000 cases in the U.S. and 132,000 in Europe annually.
Q:What is the target profile for the Phase III VESPER program?
A:The target profile includes competitive weight loss (16% predicted at week 28 for 9.6 mg) and monthly dosing for differentiation. A Phase III study will evaluate switching from weekly to monthly therapy.
Q:What is the integration status of Seagen and its impact on oncology leadership?
A:Seagen's integration is complete, with most employees retained. Multiple Phase III studies have been accelerated, including for Padcev and sigvotatug vedotin. The ADC portfolio has been expanded with new payloads and antigens.
Q:How does the PD-1-VEGF program stand out in a crowded market?
A:The PD-1-VEGF program ('4404) shows a 100-fold increase in PD-1 affinity in the presence of VEGF. Phase III programs are ongoing for colorectal, non-small cell lung, endometrial, and bladder cancers, with combinations planned with ADCs.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on certain topics, such as the full tolerability data for VESPER-3, baseline demographics, and GI side effect duration, deferring these to the ADA presentation. Additionally, they did not elaborate on potential strategies for Vyndaqel beyond 2028, citing sensitivity.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI
GIPR
GLP receptor
III study
Manufacturing Optimization
Optimization Program
Phase III
RD
VESPER study
cancer
class
dose regimen
dosing
end decade
medicine
milligram
model prediction
obesity portfolio
objective
opportunity
patient
placebo weight
potential efficacy
product portfolio
productivity
profile
readout
receptor agonist
revenue
saving
trial
weight loss
PFE Transcript
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Positive2-3
The earnings call summary indicates strong financial metrics with raised EPS guidance, significant cost savings initiatives, and ongoing product development in high-potential areas like lung cancer. Despite lower COVID-19 product performance, non-COVID products are doing well. The Q&A session revealed optimism about product pipelines and strategic AI investments. While some details were deferred, the overall sentiment is positive due to promising R&D advancements and strategic initiatives. The lack of specific market cap data limits precise impact prediction, but the positive aspects outweigh negatives, suggesting a positive stock reaction.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-12
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Neutral11-19
Lithium Royalty Corp. (LIRC:CA) Q3 2025 Earnings Call Transcript
Positive11-4
The earnings call shows strong revenue growth and a solid cash position, with a positive outlook on lithium pricing and strategic diversification through the Tungsten acquisition. The share buyback program and lack of debt further strengthen the financial health. Despite some uncertainties in shipment timing and royalty transaction timelines, the company's focus on high-return projects and stable long-term lithium demand support a positive sentiment.
PFE Slides
PFE Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
